Interleukin-21 is a critical regulator of CD4 and CD8 T cell survival during priming under interleukin-2 deprivation conditions

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Khattar, Mithun ^a   Miyahara, Yoshihiro ^a   Schroder, Paul M ^a   Xie, Aini ^b   Chen, Wenhao ^b   Stepkowski, Stanislaw M ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 MONOCLONAL ANTIBODY; INTERLEUKIN 21; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL SURVIVAL; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; IMMUNOREGULATION; LYMPHOCYTE CULTURE; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; COCULTURE TECHNIQUES; CROSS-PRIMING; INTERLEUKIN-2; INTERLEUKINS; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84897407676     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085882     Document Type: Article

References (56)

1. Stepkowski SM, Kirken RA (2006) Janus tyrosine kinases and signal transducers and activators of transcription regulate critical functions of T cells in allograft rejection and transplantation tolerance. Transplantation 82: 295-303. (Pubitemid 44223024)
2. Zhang Y, Kirken RA, Furian L, Janczewska S, Qu X, et al. (2006) Allograft rejection requires STAT5a/b-regulated antiapoptotic activity in T cells but not B cells. J Immunol 176: 128-137. (Pubitemid 43023256)
3. Johnston JA, Kawamura M, Kirken RA, Chen YQ, Blake TB, et al. (1994) Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370: 151-153. 10.1038/370151a0 [doi]. (Pubitemid 24229128)
4. Malek TR (2008) The biology of interleukin-2. Annu Rev Immunol 26: 453-479. 10.1146/annurev.immunol.26.021607.090357 [doi].
5. Liao W, Lin JX, Leonard WJ (2013) Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38: 13-25. S1074-7613(13)00011-3 [pii];10.1016/j.immuni.2013.01.004 [doi].
6. Kim HP, Kelly J, Leonard WJ (2001) The basis for IL-2-induced IL-2 receptor alpha chain gene regulation: importance of two widely separated IL-2 response elements. Immunity 15: 159-172. S1074-7613(01)00167-4 [pii].
7. Malek TR, Castro I (2010) Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33: 153-165. S1074-7613(10)00287-6 [pii];10.1016/j.immuni.2010.08.004 [doi].
8. Gong D, Malek TR (2007) Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J Immunol 178: 242-252. 178/1/242 [pii].
9. Hwang ES, Hong JH, Glimcher LH (2005) IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508. J Exp Med 202: 1289-1300. jem.20051044 [pii];10.1084/jem. 20051044 [doi].
10. Martins GA, Cimmino L, Liao J, Magnusdottir E, Calame K (2008) Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J Exp Med 205: 1959-1965. jem.20080526 [pii];10.1084/jem.20080526 [doi].
11. Shi M, Lin TH, Appell KC, Berg LJ (2008) Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 28: 763-773. S1074-7613(08)00233-1 [pii];10.1016/j.immuni.2008.04.016 [doi].
12. Liao W, Schones DE, Oh J, Cui Y, Cui K, et al. (2008) Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. Nat Immunol 9: 1288-1296. ni.1656 [pii];10.1038/ni.1656 [doi].
13. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, et al. (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371-381. (Pubitemid 46413906)
14. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, et al. (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12: 247-254. ni.1995 [pii];10.1038/ni.1995 [doi].
15. Ballesteros-Tato A, Leon B, Graf BA, Moquin A, Adams PS, et al. (2012) Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36: 847-856. S1074-7613(12)00121-5 [pii];10.1016/j.immuni.2012.02.012 [doi].
16. Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S (2012) STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med 209: 243-250. jem.20111174 [pii];10.1084/jem.20111174 [doi].
17. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, et al. (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13: 711-718. nm1585 [pii];10.1038/nm1585 [doi].
18. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, et al (2010) Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32: 79-90. S1074-7613(10)00010-5 [pii];10.1016/j.immuni.2009.11.012 [doi].
19. Castro I, Dee MJ, Malek TR (2012) Transient enhanced IL-2R signaling early during priming rapidly amplifies development of functional CD8+ T effector-memory cells. J Immunol 189: 4321-4330. jimmunol.1202067 [pii];10.4049/jimmunol.1202067 [doi].
20. Stepkowski SM, Kao J, Wang ME, Tejpal N, Podder H, et al (2005) The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol 175: 4236-4246. (Pubitemid 41361957)
21. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, et al. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878. (Pubitemid 37339629)
22. Borie DC, Changelian PS, Larson MJ, Si MS, Paniagua R, et al. (2005) Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 79: 791-801. (Pubitemid 40546198)
23. Quaedackers ME, Mol W, Korevaar SS, van Gurp EA, van Ijcken WF, et al. (2009) Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 88: 1002-1009.
24. Campara M, Tzvetanov IG, Oberholzer J (2010) Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opin Biol Ther 10: 959-969. 10.1517/14712598.2010.485187 [doi].
25. Rojas MA, Carlson NG, Miller TL, Rose JW (2009) Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2: 291-297. 10.1177/1756285609337992 [doi].
26. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164.
27. Guo Z, Khattar M, Schroder PM, Miyahara Y, Wang G, et al. (2013) A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T cells. J Immunol 190: 3153-3162. jimmunol.1200751 [pii];10.4049/jimmunol.1200751 [doi].
28. Wang G, Khattar M, Guo Z, Miyahara Y, Linkes SP, et al. (2010) IL-2- deprivation and TGF-beta are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+. Immunol Lett 132: 61-68. S0165-2478(10)00165-3 [pii];10.1016/j.imlet.2010.06.001 [doi].
29. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, et al. (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261. 0092-8674(93)80067-O [pii].
30. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, et al. (1995) Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268: 1472-1476.
31. Malek TR, Yu A, Vincek V, Scibelli P, Kong L (2002) CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17: 167-178. S1074761302003679 [pii].
32. Yu A, Zhou J, Marten N, Bergmann CC, Mammolenti M, et al. (2003) Efficient induction of primary and secondary T cell-dependent immune responses in vivo in the absence of functional IL-2 and IL-15 receptors. J Immunol 170: 236-242. (Pubitemid 36026145)
33. Spolski R, Leonard WJ (2008) Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 26: 57-79. 10.1146/annurev.immunol.26.021607.090316 [doi]. (Pubitemid 351600371)
34. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, et al. (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63. 10.1038/35040504 [doi].
35. Elsaesser H, Sauer K, Brooks DG (2009) IL-21 is required to control chronic viral infection. Science 324: 1569-1572. 1174182 [pii];10.1126/science. 1174182 [doi].
36. Yi JS, Du M, Zajac AJ (2009) A vital role for interleukin-21 in the control of a chronic viral infection. Science 324: 1572-1576. 1175194 [pii];10.1126/science.1175194 [doi].
37. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, et al. (2009) IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324: 1576-1580. 1172815 [pii];10.1126/science. 1172815 [doi].
38. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ (2008) IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A 105: 14028-14033. 0804358105 [pii];10.1073/pnas.0804358105 [doi].
39. Sutherland AP, Van BT, Wurster AL, Suto A, Michaud M, et al. (2009) Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 58: 1144-1155. db08-0882 [pii];10.2337/db08-0882 [doi].
40. McGuire HM, Vogelzang A, Ma CS, Hughes WE, Silveira PA, et al. (2011) A subset of interleukin-21 + chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity. Immunity 34: 602-615. S1074-7613(11)00131-2 [pii];10.1016/j.immuni.2011.01.021 [doi].
41. Davidson TS, DiPaolo RJ, Andersson J, Shevach EM (2007) Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol 178: 4022-4026. 178/7/4022 [pii].
42. Zurawski SM, Mosmann TR, Benedik M, Zurawski G (1986) Alterations in the amino-terminal third of mouse interleukin 2: effects on biological activity and immunoreactivity. J Immunol 137: 3354-3360. (Pubitemid 17181713)
43. Zurgil N, Shafran Y, Fixler D, Deutsch M (2002) Analysis of early apoptotic events in individual cells by fluorescence intensity and polarization measurements. Biochem Biophys Res Commun 290: 1573-1582. (Pubitemid 34687438)
44. Matarrese P, Cauda R, Malorni W (2003) Activation-associated mitochondrial hyperpolarization hijacks T cells toward an apoptosis-sensitized phenotype. Cell Death Differ 10: 609-611. (Pubitemid 36656650)
45. Strasser A, Harris AW, Vaux DL, Webb E, Bath ML, et al. (1990) Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. Curr Top Microbiol Immunol 166: 175-181.
46. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J (2006) Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927. 1122927 [pii];10.1126/science.1122927 [doi].
47. Zier KS, Leo MM, Spielman RS, Baker L (1984) Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes 33: 552-555. (Pubitemid 14113348)
48. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, et al. (2005) Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 76: 773-779. S0002-9297(07)60724-1 [pii];10.1086/429843 [doi].
49. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, et al. (2007) Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39: 329-337. ng1958 [pii];10.1038/ng1958 [doi].
50. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, et al. (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186: 3918-3926. jimmunol.1003099 [pii];10.4049/ jimmunol.1003099 [doi].
51. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, et al. (2010) IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 207: 1871-1878. jem.20100209 [pii];10.1084/jem.20100209 [doi].
52. Johnson LD, Jameson SC (2009) Immunology. A chronic need for IL-21. Science 324: 1525-1526. 324/5934/1525 [pii];10.1126/science.1176487 [doi].
53. Cubas RA, Mudd JC, Savoye AL, Perreau M, van GJ, et al. (2013) Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 19: 494-499. nm.3109 [pii];10.1038/nm.3109 [doi].
54. Perreau M, Savoye AL, De CE, Corpataux JM, Cubas R, et al. (2013) Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 210: 143-156. jem.20121932 [pii];10.1084/jem.20121932 [doi].
55. McGuire HM, Walters S, Vogelzang A, Lee CM, Webster KE, et al. (2011) Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 60: 867-875. 60/3/867 [pii];10.2337/db10-1157 [doi].
56. Petrelli A, Carvello M, Vergani A, Lee KM, Tezza S, et al. (2011) IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes 60: 3223-3234. db11-0880 [pii];10.2337/db11-0880 [doi].